All In Biotech

Drug Trial Radar · NCT05714085

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 342 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

342

Planned (sponsor's estimate)

Start

May 31, 2023

Primary completion

Aug 20, 2029

Study completion May 12, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 29 days, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

Conditions

  • Heart Failure
  • Left Ventricular Systolic Dysfunction

Interventions

  • Vericiguat tabletDrug

    2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form

  • Vericiguat suspensionDrug

    0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form

  • Placebo tabletDrug

    Placebo for vericiguat administered orally once daily in tablet form

  • Placebo suspensionDrug

    Placebo for vericiguat administered orally once daily in suspension form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Base Period: Change from baseline to Week 16 in N-terminal pro-brain natriuretic peptide (NT-proBNP)Time frame: Baseline and Week 16 of Base Period
  2. Extension Period: Percentage of participants with one or more adverse events (AEs)Time frame: Includes data collected up to a maximum of approximately 8 years
  3. Extension Period: Percentage of participants who discontinued study drug due to an AETime frame: Includes data collected up to a maximum of approximately 8 years

Locations

112 sites in 30 countries. Site status is shown where the registry gives one.

  • The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002)

    Los Angeles, California · Recruiting

  • Lucile Packard Children's Hospital ( Site 0040)

    Palo Alto, California · Recruiting

  • Loma Linda University Health System ( Site 0008)

    San Bernardino, California · Recruiting

  • Children's Hospital Colorado ( Site 0012)

    Aurora, Colorado · Completed

  • Children's National Medical Center ( Site 0020)

    Washington D.C., District of Columbia · Recruiting

  • Johns Hopkins All Children's Hospital ( Site 0029)

    St. Petersburg, Florida · Recruiting

  • Children's Healthcare of Atlanta - Arthur M. Blank Hospital ( Site 0001)

    Atlanta, Georgia · Recruiting

  • Boston Children's Hospital ( Site 0035)

    Boston, Massachusetts · Recruiting

  • C.S. Mott Children's Hospital ( Site 0033)

    Ann Arbor, Michigan · Recruiting

  • Washington University-Pediatric Cardiology/ St. Louis Children's Hospital ( Site 0006)

    St Louis, Missouri · Recruiting

  • Columbia University Medical Center-Pediatric Cardiology ( Site 0016)

    New York, New York · Recruiting

  • The Children's Hospital at Montefiore ( Site 0030)

    The Bronx, New York · Recruiting

  • Cincinnati Children's Hospital Medical Center ( Site 0034)

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic-Cleveland Clinic Chidren's ( Site 0022)

    Cleveland, Ohio · Recruiting

  • Children's Hospital of Philadelphia (CHOP) ( Site 0004)

    Philadelphia, Pennsylvania · Recruiting

  • Children's Hospital of Pittsburgh ( Site 0010)

    Pittsburgh, Pennsylvania · Recruiting

  • Le Bonheur Children's Hospital ( Site 0007)

    Memphis, Tennessee · Recruiting

  • Children's Health-The Heart Center ( Site 0015)

    Dallas, Texas · Recruiting

  • Texas Children's Hospital ( Site 0039)

    Houston, Texas · Recruiting

  • Seattle Children's Hospital-Cardiology/Fetal Therapy ( Site 0019)

    Seattle, Washington · Recruiting

  • Centre Hospitalier Régional de la Citadelle ( Site 0302)

    Liège, Liege, Belgium · Completed

  • UZ Gent ( Site 0301)

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • UZ Leuven ( Site 0300)

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • Incor - Instituto do Coracao ( Site 0400)

    São Paulo, Brazil · Recruiting

  • Instituto Dante Pazzanese de Cardiology ( Site 0402)

    São Paulo, São Paulo, Brazil · Recruiting

  • Stollery Children's Hospital ( Site 0501)

    Edmonton, Alberta, Canada · Recruiting

  • The Hospital for Sick Children ( Site 0500)

    Toronto, Ontario, Canada · Recruiting

  • Centre intégré universitaire de santé et de services sociaux-Centre de recherche du CHUS ( Site 0502)

    Sherbrooke, Quebec, Canada · Recruiting

  • Clinica Somer ( Site 0607)

    Rionegro, Antioquia, Colombia · Recruiting

  • Ciensalud Ips S A S ( Site 0608)

    Barranquilla, Atlántico, Colombia · Recruiting

  • Fundación Cardioinfantil Instituto de Cardiología ( Site 0603)

    Bogotá, Bogota D.C., Colombia · Recruiting

  • Fundación Valle del Lili ( Site 0604)

    Cali, Valle del Cauca Department, Colombia · Recruiting

  • Clínica Imbanaco S.A.S ( Site 0602)

    Cali, Valle del Cauca Department, Colombia · Recruiting

  • Klinički bolnički centar Zagreb ( Site 3700)

    Zagreb, City of Zagreb, Croatia · Recruiting

  • Rigshospitalet-BørneUngeAfdelingen ( Site 0800)

    Copenhagen, Capital Region, Denmark · Recruiting

  • Tampereen yliopistollinen sairaala-Pediatric Early Phase Trials Unit ( Site 0900)

    Tampere, Pirkanmaa, Finland · Recruiting

  • Hôpital Universitaire Necker Enfants Malades ( Site 1001)

    Paris, France · Completed

  • Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universita ( Site 1004)

    Paris, France · Completed

  • CHU Bordeaux Haut-Leveque ( Site 1000)

    Pessac, Aquitaine, France · Completed

  • Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1002)

    Nantes, Loire-Atlantique, France · Completed

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.